Stock Analysis
- Switzerland
- /
- Biotech
- /
- SWX:IDIA
Idorsia Full Year 2023 Earnings: CHF1.67 loss per share (vs CHF4.67 loss in FY 2022)
Idorsia (VTX:IDIA) Full Year 2023 Results
Key Financial Results
- Revenue: CHF152.4m (up 57% from FY 2022).
- Net loss: CHF297.9m (loss narrowed by 64% from FY 2022).
- CHF1.67 loss per share (improved from CHF4.67 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Idorsia Earnings Insights
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
Performance of the market in Switzerland.
The company's shares are down 3.8% from a week ago.
Risk Analysis
You should learn about the 4 warning signs we've spotted with Idorsia (including 3 which don't sit too well with us).
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:IDIA
Idorsia
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland.